<span item_type="fundamental" item_id="52dec734fa0c4764bddb175d449bb84f" counter_id="ST/US/APUS" env="prod"></span><span item_type="announcement" item_id="551257199910521601" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.26.</p><p></p><h3>Segment Revenue</h3><ul><li>The company operates as a single segment and has not generated any revenue as of June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1894525/000121390025078507/ea0251232-10q_apimeds.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: For the three months ended June 30, 2025, the net loss was $2,662,193, compared to $449,363 for the same period in 2024, representing an increase in loss of $2,212,830.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1894525/000121390025078507/ea0251232-10q_apimeds.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses for the three months ended June 30, 2025, were $2,663,904, compared to $427,757 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1894525/000121390025078507/ea0251232-10q_apimeds.htm"></span></li><li><strong>Research and Development Expenses</strong>: For the three months ended June 30, 2025, research and development expenses were $651,784, compared to no expenses for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1894525/000121390025078507/ea0251232-10q_apimeds.htm"></span></li><li><strong>General and Administrative Expenses</strong>: For the three months ended June 30, 2025, general and administrative expenses were $2,012,120, compared to $427,757 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1894525/000121390025078507/ea0251232-10q_apimeds.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the six months ended June 30, 2025, net cash used in operating activities was $3,381,409, compared to $447,155 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1894525/000121390025078507/ea0251232-10q_apimeds.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: For the six months ended June 30, 2025, net cash provided by financing activities was $12,126,646, compared to $100,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1894525/000121390025078507/ea0251232-10q_apimeds.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>IPO Proceeds</strong>: On May 12, 2025, the company completed its IPO, generating net proceeds of $11.9 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1894525/000121390025078507/ea0251232-10q_apimeds.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to advance Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1894525/000121390025078507/ea0251232-10q_apimeds.htm"></span></li><li><strong>Liquidity</strong>: The company believes its cash will be sufficient to fund its current operating plan through at least the next twelve months from the date of issuance of the accompanying condensed financial statements.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1894525/000121390025078507/ea0251232-10q_apimeds.htm"></span></li></ul>

Apimeds Pharmaceuticals US | 10-Q: FY2025 Q2 EPS: USD -0.26